Interstitial lung disease and leflunornide use

Aiyappan, V.
September 2006
Thorax;Sep2006, Vol. 61 Issue 9, p827
Academic Journal
The article focuses on the study that examines the risk of developing interstitial lung disease (ILD) in patients taking a disease modifying anti-rheumatic drug leflunomide in Great Britain. The study employed 62,734 patients with rheumatoid arthritis. It was found that the risk of ILD was not higher for patients taking leflunomide given that they had no history of ILD.


Related Articles

  • Adverse Reaction Research.  // Reactions Weekly;8/25/2007, Issue 1166, p4 

    The section discusses research on the association between leflunomide and interstitial lung disease (ILD). It references a study by Ju J. H. and colleagues, published in the June 2007 issue of "Arthritis and Rheumatism." The researchers found that leflunomide increases the risk of ILD in Korean...

  • Interstitial Lung Disease Related to Rheumatoid Arthritis: Evolution After Treatment. Rojas-Serrano, Jorge; González-Velásquez, Edilzar; Mejía, Mayra; Sánchez-Rodríguez, Alain; Carrillo, Guillermo // Reumatologia Clinica;mar/abr2012, Vol. 8 Issue 2, p68 

    Objective: To describe the evolution of lung function in a cohort of rheumatoid arthritis (RA) patients with interstitial lung disease (ILD) treated according to the medical judgment of attending physicians. Methods: Retrospective cohort of RA patients with ILD, defined by a restrictive pattern...

  • Pharmacovigilance & Regulatory News.  // Reactions Weekly;7/3/2004, Issue 1008, p2 

    Presents news briefs on pharmaceutical policy as of July 3, 2004. Revision to the Canadian Product Monographs for clozapine products; Update on the labelling of several antidepressants; Safety information regarding reports of interstitial lung disease associated with leflunomide use.

  • Induction of EMT-like phenotypes by an active metabolite of leflunomide and its contribution to pulmonary fibrosis. Namba, T.; Tanaka, K.-I.; Ito, Y.; Hoshino, T.; Matoyama, M.; Yamakawa, N.; Isohama, Y.; Azuma, A.; Mizushima, T. // Cell Death & Differentiation;Dec2010, Vol. 17 Issue 12, p1882 

    Drug-induced interstitial lung disease (ILD), particularly pulmonary fibrosis, is a serious clinical concern and myofibroblasts have been suggested to have a major role, with it recently being revealed that some of these myofibroblasts are derived from lung epithelial cells through...

  • Interstitial lung diseases after leflunomide use in nephropathy: an analysis of reported cases in Chinese literature. Zhang, Wu-xing; Zhou, Wei; Zhang, Zhi-qiang; Zhao, Xue-wei // Nephrology Dialysis Transplantation;Apr2011, Vol. 26 Issue 4, p1416 

    Background. Leflunomide (LEF)-induced interstitial lung disease (ILD) has been reported in patients with rheumatoid arthritis. In China, LEF is used off-label for the treatment of nephropathy.Methods. Systemic review of the Chinese literature from 1999 to June 2010 for case reports and case...

  • Leflunomide-linked ILD reported to ADRAC.  // Reactions Weekly;12/16/2006, Issue 1132, p2 

    This article focuses on reports received by the Australian Adverse Drug Reactions Advisory Committee (ADRAC) regarding the link between leflunomide use and respiratory symptoms. ADRAC said there were 22 reports involving one or more reactions, including lung infiltration, pulmonary fibrosis,...

  • Clinical pharmacokinetics of leflunomide. Rozman, B.; Rozman, Blaz // Clinical Pharmacokinetics;2002, Vol. 41 Issue 6, p421 

    Leflunomide is the first disease-modifying antirheumatic drug to be approved for rheumatoid arthritis in the past 10 years. Orally administered leflunomide is almost completely converted into its active metabolite A77 1726 (hereafter referred to as M1). M1 displays linear pharmacokinetics at the...

  • The effect of various disease-modifying anti-rheumatic drugs on the suppressive function of CD4CD25 regulatory T cells. Oh, Ji; Kim, Yong-Gil; Lee, Seung; So, Min; Choi, Seung; Lee, Chang-Keun; Yoo, Bin // Rheumatology International;Feb2013, Vol. 33 Issue 2, p381 

    Accumulating evidence suggests that defects in the function of CD4CD25 regulatory T cells (Tregs) are important in immune-mediated diseases such as rheumatoid arthritis. Here, we investigated the effects of various disease-modifying anti-rheumatic drugs (DMARDs) on Treg function. Tregs and...

  • Adding leflunomide to DMARD sequence in Germany pays off.  // PharmacoEconomics & Outcomes News;5/21/2005, Issue 478, p6 

    Provides information on a study conducted by researchers from Germany which evaluated the costs and outcomes associated with adding leflunomide to sequential disease-modifying antirheumatic drugs. Drug options for the management of rheumatoid arthritis; Aim of the first analysis of the...


Read the Article


Sign out of this library

Other Topics